LGP's strategic share issuance and financial performance

Little Green Pharma (ASX:LGP), a global medicinal cannabis company, has issued 1,112,389 fully paid ordinary shares as consideration for services. This move was made without the need for disclosure under Part 6D.2 of the Corporations Act 2001. LGP confirms compliance with Chapter 2M and section 674 of the Act and states there is no excluded information requiring disclosure currently. The company reports impressive financial growth with quarterly revenue of $10.2 million and cash receipts of $10.8 million, marking substantial increases compared to the previous quarter.

LGP's future outlook and strategic focus

Little Green Pharma (ASX:LGP) has successfully issued 1,112,389 shares for services, demonstrating its strategic approach to compensation without disclosure requirements. The company remains in full compliance with the Corporations Act, signaling transparency and adherence to regulations. LGP's financial performance reflects significant growth, with a strong increase in revenue and cash receipts, alongside a positive cash flow. The company is focused on expanding its global operations, enhancing patient access, and innovating new delivery systems for its medicinal cannabis products. As a leader in the industry, LGP is committed to sustainability and investor engagement, positioning itself for continued success in the global market.

Executive insights on LGP's financial growth

Little Green Pharma has demonstrated strong financial growth this quarter, with a 40% increase in revenue and over 30% rise in cash receipts. Our positive cash flow of $0.4 million highlights our robust operational capabilities and commitment to shareholder value. We continue to focus on expanding our global reach and improving patient access to high-quality medicinal cannabis products.